INTERNATIONAL MEDICAL UNIVERSITY
Background and Objective: Adenomyosis is a common benign endometrial disease which causes abnormal uterine bleeding in premenopausal women and affects the quality of life. The definitive treatment is hysterectomy, however medical treatment is an option for those who wish to preserve fertility. This systematic review aims to assess the efficacy of levonorgestrel-releasing intrauterine device as medical management in women who have adenomyosis.
Methods: We searched PubMed, Cochrane and Scopus databases from 2000 to November 2019 for relevant studies containing the use of levonorgestrel-releasing intrauterine device (LNG-IUD) in managing patients with ultrasonographic diagnosed adenomyosis. Main outcomes measures in the study are menstrual blood loss (milliliters), pain score measured in 10cm-visual analogue scale, and uterine volume.
Results: Pooled results from meta-analysis showed that after LNG-IUD treatment for adenomyosis, there is significant reduction in dysmenorrhoea measured using Visual Analogue Scale after six months Standardized Mean Difference (SMD), ( 3.68; CI: 2.11-5.25), twelve months (SMD: 4.23; CI: 2.99-5.48), 24 months (SMD: 4.69; CI: 3.40-5.97) and 36 months (SMD: 4.01; CI: 3.57-4.45); significant reduction in menstrual bleeding after six months (SMD: 2.52; CI: 1.15-3.89), twelve months (SMD: 3.43; CI: 1.64-5.22) and 24 months (SMD: 3.57; CI: 1.88-5.26); significant reduction in uterine volume after six months (SMD: 0.49; CI: 0.04-0.93), twelve months (SMD: 0.80; CI: 0.11-1.48) and 24 months (SMD: 0.86; CI: 0.15-1.58).
Conclusion LNG-IUS is an effective method in alleviating the symptoms of adenomyosis. It is a valuable long-term alternative for the treatment of adenomyosis for young and perimenopausal women in terms of dysmenorrhoea and heavy menstrual bleeding.
- References: 1. Peric H, Fraser I. The symptomatology of adenomyosis. Best Practice & Research Clinical Obstetrics & Gynaecology. 2006;20(4):547-555. 2. Garcia L, Isaacson K. Adenomyosis: Review of the Literature. Journal of Minimally Invasive Gynecology. 2011;18(4):428-437 3. Osada H. Uterine adenomyosis and adenomyoma: the surgical approach. Fertility and Sterility. 2018;109(3):406-417. 4. Vannuccini S, Petraglia F. Recent advances in understanding and managing adenomyosis. F1000Research. 2019;8:283. 5. Sheng J, Zhang W, Zhang J, Lu D. The LNG-IUS study on adenomyosis: a 3-year follow-up study on the efficacy and side effects of the use of levonorgestrel intrauterine system for the treatment of dysmenorrhea associated with adenomyosis. Contraception. 2009;79(3):189-193 6. Bergeron C, Amant F. Pathology and physiopathology of adenomyosis. Best Practice & Research Clinical Obstetrics and Gynaecology. 2006; 20(4):511-521 7. Li JJ, Chung JPW, Wang S, Li TC, Duan H. The investigation and management of adenomyosis in women who wish to improve or preserve fertility. BioMed Research International. 2018;1-12. 8. Morassutto C, Monasta L, Ricci G, Barbone F, Ronfani L. Incidence and Estimated Prevalence of Endometriosis and Adenomyosis in Northeast Italy: A Data Linkage Study. Plos One. 2016;11(4). 9. Yeniel O, Cirpan T, Ulukus M, Ozabal A, Gundem G, Ozsener S, Zekioglu and Yilmaz H. Adenomyosis: prevalence, risk factors, symptoms and clinical findings. Clinical and experimental obstetrics and gynecology. 2007;34(3):163-7. 10. Leyendecker G. Endometriosis results from the dislocation of basal endometrium. Human Reproduction. 2002;17(10):2725-2736 11. Cuschieri S. The STROBE guidelines. Saudi J Anaesth. 2019;13(Suppl 1):S31. doi: 10.4103/sja.SJA_543_18. 12. Wells G, Shea B, O’Connell D, Peterson J, Welch V, Losos M, Tugwell P: The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. 2013, http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp, 13. Abbas AM, Samy A, Atwa K, Ghoneim HM, Lotfy M et al. The role of levonorgestrel inta-uterine system in the management of adenomyosis: A systematic review and meta-analysis of prospective studies. Acta Obstet Gyn Scan. 2019;99(5) 14. Jie S, Zhang WY, Zhang JP, Lu D. The LNG-IUS study on adenomyosis: a 3-year follow-up study on the efficacy and side effects of the use of levonorgestrel intrauterine system for the treatment of dysmenorrhea associated with adenomyosis. Contraception. 2009;97(3):189-193. 15. Cho SH, Anna N, Kim HY, Chay DB, Park KH, Cho DJ et al. Clinical effects of levonorgestrel-releasing intrauterine device in patients with adenomyosis. AJOG. 2008;198(4): 373.e1-7. 16. Farquhar C, Brosens I. Medical and surgical management of adenomyosis. Best Pract Res Clin Obstet Gynaecol. 2006;20(4):603-616 17. Benagiano G, Brosens I. History of adenomyosis. Best Practice & Research Clinical Obstetrics & Gynaecology. 2006;20(4):449-463. 18. Fadia JA, Hind AKS, Hayder AF. Levonorgestrel-releasing intrauterine system in adenomyosis; predictors for response and clinical outcome. Asian J Pharm Clin Res. 2018;11(12): 214-217. 19. Taran FA, Stewart EA, Brucker S. Adenomyosis: Epidemiology, Risk Factors, Clinical Phenotype and SUrgical and Interventional Alternatives to Hysterectomy. Geburtshilfe Frauenheilkd. 2013 Sep; 73(9): 924-931 20. Garcia L, Isaacson K. Adenomyosis: Review of the Literature. Journal of Minimally Invasive Gynecology. 2011;18(4):428-437. 21. Tsui K, Lee W, Chen C, Sheu B, Yen M, Chang T et al. Medical treatment for adenomyosis and/or adenomyoma. Taiwanese Journal of Obstetrics and Gynecology. 2014;53(4):459-465 22. Lei L. Leng JH, Jia SZ, Lang JH. Treatment of symptomatic adenomyosis with the levonorgestrel-releasing intrauterine system. Int J Gynecol Obstet. 2019;146(3):1-7.